

Table S1 Patients' PAH-specific medication at time of right heart catheterization.

| Medication | All patients | PAH | CTEPH |
|---|---------------------|-------------|--------------|
| Patients with GFR >60 [ml/min/1.73 m²] | | | |
| Oral endothelin receptor antagonists | 33/56 (59%) | 25/38 (66%) | 8/17 (47%) |
| Oral phosphodiesterase type 5 inhibitors | 24/56 (43%) | 22/38 (58%) | 6/17 (35%) |
| Inhaled prostacyclin | 9/56 (16%) | 9/38 (24%) | - |
| Patients with GFR ≤60 [ml/min/1.73 m²] | | | |
| Oral endothelin receptor antagonists | 30/40 (75%) | 22/31 (71%) | 2/8 (25%) |
| Oral phosphodiesterase type 5 inhibitors | 33/40 (83%) | 30/31 (65%) | 3/8 (38%) |
| Inhaled prostacyclin | 8/40 (20%) | 8/31 (26%) | - |